Quartz Partners LLC Makes New $1.61 Million Investment in ANI Pharmaceuticals, Inc. $ANIP

Quartz Partners LLC acquired a new stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 19,424 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,608,000. Quartz Partners LLC owned 0.09% of ANI Pharmaceuticals at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in shares of ANI Pharmaceuticals by 2.2% during the fourth quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company’s stock worth $103,022,000 after purchasing an additional 27,598 shares during the period. State Street Corp lifted its holdings in ANI Pharmaceuticals by 2.2% in the 4th quarter. State Street Corp now owns 727,204 shares of the specialty pharmaceutical company’s stock worth $57,405,000 after buying an additional 15,496 shares during the period. UBS Group AG lifted its holdings in ANI Pharmaceuticals by 45.8% in the 3rd quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock worth $54,032,000 after buying an additional 185,172 shares during the period. Arrowstreet Capital Limited Partnership grew its position in shares of ANI Pharmaceuticals by 19.3% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 564,360 shares of the specialty pharmaceutical company’s stock worth $43,399,000 after buying an additional 91,153 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in shares of ANI Pharmaceuticals by 8.9% during the first quarter. Dimensional Fund Advisors LP now owns 531,190 shares of the specialty pharmaceutical company’s stock valued at $40,843,000 after buying an additional 43,523 shares during the period. 76.05% of the stock is owned by institutional investors.

ANI Pharmaceuticals Stock Up 1.5%

Shares of NASDAQ:ANIP opened at $78.02 on Thursday. The firm has a market capitalization of $1.79 billion, a P/E ratio of 16.81 and a beta of 0.44. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.41 and a current ratio of 2.91. The stock has a 50 day moving average price of $80.57 and a 200-day moving average price of $78.94. ANI Pharmaceuticals, Inc. has a 52-week low of $70.15 and a 52-week high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, beating the consensus estimate of $2.04 by $0.17. The company had revenue of $266.04 million for the quarter, compared to analyst estimates of $260.13 million. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The firm’s revenue was up 25.8% on a year-over-year basis. During the same period in the previous year, the company posted $1.80 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, equities research analysts anticipate that ANI Pharmaceuticals, Inc. will post 7.83 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on ANIP. Wall Street Zen downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Zacks Research cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Canaccord Genuity Group reduced their price objective on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a research report on Monday, August 10th. Guggenheim dropped their target price on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a research report on Monday, August 10th. Finally, Weiss Ratings lowered shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, August 11th. Four analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, ANI Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $105.83.

Insider Buying and Selling at ANI Pharmaceuticals

In other news, CFO Stephen P. Carey sold 3,313 shares of ANI Pharmaceuticals stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $86.00, for a total transaction of $284,918.00. Following the completion of the transaction, the chief financial officer directly owned 177,543 shares in the company, valued at approximately $15,268,698. This trade represents a 1.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Thomas Haughey sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $80.88, for a total value of $161,760.00. Following the completion of the sale, the director directly owned 38,878 shares in the company, valued at approximately $3,144,452.64. This represents a 4.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 18,987 shares of company stock worth $1,546,405 over the last three months. Company insiders own 8.10% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.